Number of vials.

No definition available.

Name:	AIM_NumberOfVials
Namespace Prefix:	AIM_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and development expense cost estimated lives.

+ References

No definition available.

+ Details

Name:	AIM_ResearchAndDevelopmentExpenseCostEstimatedLives
Namespace Prefix:	AIM_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Units manufactured.

+ References

No definition available.

+ Details

Name:	AIM_UnitsManufactured
Namespace Prefix:	AIM_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of maintenance incurred and directly related to good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostMaintenance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 932
-SubTopic 360
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 932
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-10(c)(7)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1

+ Details

Name:	us-gaap_DevelopmentCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_InventoryWorkInProcessAndRawMaterials
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_AdvancedPancreaticCancerStudyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDStudyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=AIM_JubilantHollisterStierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_AmpligenManufacturingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=AIM_SterlingPharmaSolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=AIM_ErasmusUniversityMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_JointClinicalStudyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=AIM_AzenovaLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_ConsultingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=AIM_AlcamiCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=AIM_QualityControlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=AIM_RegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research, Consulting and Supply Agreements (Details Narrative)	1 Months Ended				3 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Apr. 30, 2022 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($) Integer	Dec. 31, 2023 USD ($)	Dec. 31, 2017 Integer	Oct. 31, 2023 USD ($) shares
Research and development expense					$ 1,951,000	$ 2,052,000
Amarex Clinical Research LLC [Member]
Research and development expense					521,000	455,000
Research and development expense excluding acquired in process cost			$ 6,400,000	$ 8,400,000
Development cost			125,000	$ 1,000,000			$ 6,600,000
Estimated lives				4 years 7 months 6 days
Invigilators cost			$ 4,400,000
Amarex Clinical Research LLC [Member] \| Advanced Pancreatic Cancer Study Agreement [Member]
Research and development expense					86,000	174,000
Amarex Clinical Research LLC [Member] \| Post COVID Study Agreement [Member]
Research and development expense					435,000	$ 281,000
Jubilant HollisterStier [Member]
Number of units manufactured \| Integer								16,000
Additional number of vials \| Integer						27,900
Inventory work in process and raw materials						$ 1,432,000
Jubilant HollisterStier [Member] \| Ampligen Manufacturing Agreement [Member]
Research and development expense					1,000
Sterling Pharma Solutions [Member] \| Master Service Agreement and Quality Agreement [Member]
Research and development expense					129,000	357,000
Erasmus University Medical Center [Member] \| Joint Clinical Study Agreement [Member]
Research and development expense		$ 200,000			4,000
Azenova LLC [Member] \| Consulting Agreement [Member]
Research and development expense					90,000
Stock options, aggregate intrinsic value									$ 30,000
Stock options, vested \| shares									360,000
Alcami Corporation [Member]
Research and development expense	$ 30,000				10,000	$ 8,000
Clinical Studies [Member]
Research and development expense					948,000
Manufacturing and Engineering [Member]
Research and development expense					246,000
Quality Control [Member]
Research and development expense					550,000
Regulatory [Member]
Research and development expense					$ 207,000